APOE ɛ4 Carriers Show Delayed Recovery of Verbal Memory and Smaller Entorhinal Volume in the First Year After Ischemic Stroke.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2019
Historique:
pubmed: 6 8 2019
medline: 21 10 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

The apolipoprotein E (APOE) gene ɛ4 allele is a risk factor for Alzheimer's disease and cardiovascular disease. However, its relationship with cognition and brain volume after stroke is not clear. We compared cognition and medial temporal lobe volumes in APOEɛ4 carriers and non-carriers in the first year after ischemic stroke. We sampled 20 APOEɛ4 carriers and 20 non-carriers from a larger cohort of 135 ischemic stroke participants in the longitudinal CANVAS study. Participants were matched on a range of demographic and stroke characteristics. We used linear mixed-effect models to compare cognitive domain z-scores (attention, processing speed, executive function, verbal and visual memory, language, visuospatial function) and regional medial temporal lobe volumes (hippocampal, entorhinal cortex) between groups at each time-point (3, 12-months post-stroke), and within groups across time-points. APOE gene single nucleotide polymorphisms (SNPs; rs7412, rs429358) were genotyped on venous blood. APOEɛ4 carriers and non-carriers did not differ on any demographic, clinical, or stroke variable. Carriers performed worse than non-carriers in verbal memory at 3 months post-stroke (p = 0.046), but were better in executive function at 12 months (p = 0.035). Carriers demonstrated a significant improvement in verbal memory (p = 0.012) and executive function (p = 0.015) between time-points. Non-carriers demonstrated a significant improvement in visual memory (p = 0.0005). Carriers had smaller bilateral entorhinal cortex volumes (p < 0.05), and larger right sided and contralesional hippocampal volumes, at both time-points (p < 0.05). APOE ɛ4 is associated with delayed recovery of verbal memory function and reduced entorhinal cortex volumes in the first year after ischemic stroke.

Sections du résumé

BACKGROUND
The apolipoprotein E (APOE) gene ɛ4 allele is a risk factor for Alzheimer's disease and cardiovascular disease. However, its relationship with cognition and brain volume after stroke is not clear.
OBJECTIVE
We compared cognition and medial temporal lobe volumes in APOEɛ4 carriers and non-carriers in the first year after ischemic stroke.
METHODS
We sampled 20 APOEɛ4 carriers and 20 non-carriers from a larger cohort of 135 ischemic stroke participants in the longitudinal CANVAS study. Participants were matched on a range of demographic and stroke characteristics. We used linear mixed-effect models to compare cognitive domain z-scores (attention, processing speed, executive function, verbal and visual memory, language, visuospatial function) and regional medial temporal lobe volumes (hippocampal, entorhinal cortex) between groups at each time-point (3, 12-months post-stroke), and within groups across time-points. APOE gene single nucleotide polymorphisms (SNPs; rs7412, rs429358) were genotyped on venous blood.
RESULTS
APOEɛ4 carriers and non-carriers did not differ on any demographic, clinical, or stroke variable. Carriers performed worse than non-carriers in verbal memory at 3 months post-stroke (p = 0.046), but were better in executive function at 12 months (p = 0.035). Carriers demonstrated a significant improvement in verbal memory (p = 0.012) and executive function (p = 0.015) between time-points. Non-carriers demonstrated a significant improvement in visual memory (p = 0.0005). Carriers had smaller bilateral entorhinal cortex volumes (p < 0.05), and larger right sided and contralesional hippocampal volumes, at both time-points (p < 0.05).
CONCLUSION
APOE ɛ4 is associated with delayed recovery of verbal memory function and reduced entorhinal cortex volumes in the first year after ischemic stroke.

Identifiants

pubmed: 31381519
pii: JAD190566
doi: 10.3233/JAD-190566
doi:

Substances chimiques

Apolipoprotein E4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-259

Auteurs

Emilio Werden (E)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Mohamed Salah Khlif (MS)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Laura J Bird (LJ)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Toby Cumming (T)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Jennifer Bradshaw (J)

Austin Health, Heidelberg, Melbourne, VIC, Australia.

Wasim Khan (W)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Matthew Pase (M)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Carolina Restrepo (C)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Michele Veldsman (M)

Department of Experimental Psychology, University of Oxford, Oxford, UK.

Natalia Egorova (N)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.
Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.

Sheila K Patel (SK)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Elie Gottlieb (E)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Amy Brodtmann (A)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.
Austin Health, Heidelberg, Melbourne, VIC, Australia.
Eastern Clinical Research Unit, Box Hill Hospital, Melbourne, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH